Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1993-12-21
1995-09-05
Clardy, S. Mark
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514428, 514448, A61K 3138, A61K 3140, A61K, A61K
Patent
active
054479410
ABSTRACT:
A method of inhibiting pulmonary hypertensive disease comprising administering to a human in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, --CH.sub.3, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
REFERENCES:
patent: 4133814 (1979-01-01), Jones et al.
patent: 4380635 (1983-04-01), Peters
patent: 4418068 (1983-11-01), Jones
patent: 5075321 (1991-12-01), Schreiber
U.S. application Ser. No. 07/920,933 filed on Jul. 28, 1992 to Black et al.
U.S. application Ser. No. 07/995,222 filed on Dec. 22, 1992 to Black et al.
U.S. application Ser. No. 08/035,121 filed on Mar. 19, 1993 to Black et al.
U.S. application Ser. No. 08/082218 filed on Jun. 24, 1993 to Cullinan et al.
U.S. application Ser. No. 08/096,480 filed on Jul. 22,1993 to Hock.
U.S. application Ser. No. 08/112,012 filed on Aug. 15, 1993 to Dodge et al.
U.S. application Ser. No. 08/111,796 filed on Aug. 25, 1993 to Dodge et al.
U.S. application Ser. No. 08/081,610 filed on Jun. 21, 1993 to Yang.
Draper et al., "Effects of Raloxifene (LY139481 HC1) on Biochemical Markers of Bone and Lipid Metabolism i Healthy Postmenopausal Women", Hong Kong, Fourth IntSymp. on Osteoporosis, Mar. 29, 1993.
Bryant et al., "Protection from Bone Loss and Lowering of Serum Cholesterol in the Absence of Uterine Stimulation in Ovariectomized Rats", Am Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Evans et al., "Raloxifence is a Tissue Specific Estrogen Agonist", Am Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Frolick et al., "In Vivo and In Vitro Metabolism of Raloxifene", Am. Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Glasebrook et al., "Multiple Binding Sites for the Anti-estrogen Raloxifene", Am Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Hock et al., "Combination of Raloxifene and Human Parathyoid Hormone 1-34; Increased Femur Bone Mass in Young Ovariectomized (OVX) Rats", Am. Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Sato et al., "DEXA Analysis of Raloxifene Effects on the Bones From Ovariectomized Rats", Am. Soc. for Bone and Min. Res., Tampa, Sep. 18-22, 1993.
Yang et al., "Raloxifene an Anti-Estogen, Simulates the Effects of Estogen in Inhibiting Bone Resorption Through Regulating TGFB-3 Expression in Bone;" .Am Soc. for Bone and Min. Res., Tampa, Sep. 18-22, 1993.
Black et al., "Distinct, Structure-Related Profiles of Estrogenic and Anti-Estrogenic Activity in the Tamoxifen and LY117018 Series;" The Endocrine Society, Abstract 1982.
Black et al., "Uterine Bioassay of Tamoxifen, Trioxifene, and New Estrogen Antagonist (LY117018) in Rats and Mice," Life Sciences, 26:1980, 1453-1458.
Black et al., "Differential Interaction of Antiestrogens with Cytosol Estrogen Receptors," Molecular and Cellular Endocrinology, 22:1981, 95-103.
Black et al., "Evidence for Biological Action of the Antiestrogens LY117018 and Tamoxifen by Different Mechanisms," Endocrinology 109;1981, 987-989.
Black, L. J. "Biological Actions and Binding Properites of a New Estrogen Antagosist LY117018," In: Homone Antagonists, 129-82, 1982 (M. K. Agarwal ed.) Walter de Gruyter and Co., Berlin New York.
Black et al., LY156758: A Unique Antiestrogen Displaying High Affinity for Estrogen Receptors, Negligible Estrogenic Activity and Near-Total Estrogen Antagonism in Vivo. Presented at the Fifth Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, Nov. 5-6, 1982.
Black et al., Antagonism of Estrogen Action with a New benzothiophene Derived Antiestrogen, Life Sciences, 32:1983. 1031-1036.
Black et al., The Relationship of the Antiestrogenic Efficacy of LY156758 to its Pharmacokinetics and Metabolism Following Oral Administration to Adult Ovariectomized Rats, Seventh International Congress of Endocrinology, Quebec City, Canada, Jul. 1-7, 1984, abs. 323.
Jones et al., Synthesis and Antiestrogenic Activity of [3,4-Dihydro-2(4-methoxyphenyl)-1-napthalenyl] [4-[2-pyrrolidinyl)ethoxy1]-phenyl] methanone, methanesulfonic acid salt, Journal of Medicinal Chemistry 22;1979, 962-966.
Jones et al., Antiestrogens 2. Structure Activity Studies in a Series of 3-Aroyl-2-arylbenzo[b]thiophene Derivatives Leading to [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)etho xy]-phenyl]methanone Hydrochloride (LY156758), a Remarkably Effective Estrogen Antagonist with Only Minimal Intrinsic Estrogenicity, J. Med. Chem. 27(8), 1984, 1057-1066.
Rubin, Primary Pulmonary Hypertension, Drugs, 43(1), 37-43 (1992).
Rubin, Primary Pulmonary Hypertension, Chest, 104, 236-250 (1993).
Sato et al., Association of Sjogren's Syndrome with Pulmonary Hypertension, Human Path, 24(2), 199-205 (1993).
Rich et al., Primary Pulmonary Hypertension, Ann of Int Med, 107, 216-223, (1987).
Palevsky et al., The Management of Primary Pulmonary Hypertension, JAMA, 265(8), 1014-1020 (1991).
Fahrat et al., Br J Pharm, 110, 719-723 (1993).
Gordon et al., J Appl Physiol, 2116-2121, (1986).
Reindel et al., Tox and Appld Pharm, 106, 179-200 (1990).
Fahrat et al., The J Pharm and Exp Therapeutics, 261(2), 686-691 (1992).
Clardy S. Mark
Dahling Gerald V.
Eli Lilly and Company
Sales James J.
LandOfFree
Methods of inhibiting pulmonary hypertensive diseases with ralox does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of inhibiting pulmonary hypertensive diseases with ralox, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of inhibiting pulmonary hypertensive diseases with ralox will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-472963